Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

atamparib escalation levels

Preclinical

NNerviano Medical Sciences (Shanghai) Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

NSCLC AdenocarcinomaRecruiting

NSCLC AdenocarcinomaPreclinical

Recruiting

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

NSCLC Adenocarcinoma

NCT07374419

Clinical

Trials by Indication[1]

NSCLC Adenocarcinoma1 trial

A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors

Recruiting·NNerviano Medical Sciences (Shanghai) Ltd.·Preclinical·NCT07374419·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for atamparib escalation levels. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for atamparib escalation levels. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nerviano Medical Sciences (Shanghai) Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: NNerviano Medical Sciences (Shanghai) Ltd.

Related News